Clinical Trial

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 6, 2025 (before its estimated May 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812 following single and multiple SC administrations in normal to overweight or obese but otherwise healthy subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-31.
Trial Details
NCT Number NCT07224399
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Conditions Healhty, Overweight or Obesity
Enrollment 60 participants
Start Date 2025-10-09
Primary Completion 2026-05-15 (estimated)
Study Completion 2026-05-15 (estimated)
Updated on ClinicalTrials.gov 2025-11-06